Ado-trastuzumab emtansine (T-DM1) was recently approved for patients with human epidermal growth factor receptor 2 positive (HER2+) early breast cancer (eBC) with residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment. Cost-effectiveness analysis was conducted to compare T-DM1 versus trastuzumab in the United States.

中文翻译：

---

Ado-trastuzumab Emtansine (T-DM1) 用于辅助治疗美国残留浸润性 HER2+ 早期乳腺癌患者的成本效益分析。

Ado-trastuzumab emtansine (T-DM1) 最近被批准用于在新辅助紫杉烷和曲妥珠单抗治疗后残留浸润性疾病的人表皮生长因子受体 2 阳性 (HER2+) 早期乳腺癌 (eBC) 患者。在美国进行了成本效益分析以比较 T-DM1 与曲妥珠单抗。